Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 8/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492969 | 1.00 | RELA (1.00) | RELANFE2L2NQO2ABL1ABCB1 | |
| 2-Hydroxy-4'-Methoxystilbene SCHEMBL8968277 | 0.86 | RELA (0.76) | RELANFE2L2NQO2ABL1ABCB1 | |
| 2-Hydroxy-4'-Methoxystilbene SCHEMBL8968276 | 0.86 | RELA (0.76) | RELANFE2L2NQO2ABL1ABCB1 | |
| SCHEMBL28472138 | 0.85 | ABL1 (0.75) | RELANFE2L2ABL1ABCB1BCR | |
| SCHEMBL3043458 | 0.85 | ABL1 (0.75) | RELANFE2L2ABL1ABCB1BCR | |
| SCHEMBL15286224 | 0.85 | RELA (0.73) | RELANFE2L2NQO2ABL1ABCB1 | |
| SCHEMBL17680678 | 0.84 | RELA (0.72) | RELANFE2L2NQO2ABL1ABCB1 | |
| SCHEMBL30798834 | 0.81 | RELA (0.68) | RELANFE2L2NQO2ABL1ABCB1 | |
| SCHEMBL631997 | 0.80 | TRPA1 (0.76) | RELANFE2L2NQO2ABL1ABCB1 | |
| SCHEMBL631996 | 0.80 | TRPA1 (0.76) | RELANFE2L2NQO2ABL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020112998-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | STC.UNM (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | STC UNM (US) | 2019-05-30 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | NFKBIA, NFE2L2, NFKB2 | RELA 4/4885NFE2L2 2/4885NQO2 777/4885 |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | RELA 29/4885NFE2L2 696/4885NQO2 344/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | RELA 32/4885NFE2L2 9/4885NQO2 416/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | RELA 12/4885NFE2L2 68/4885NQO2 869/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | RELA 10/4885NFE2L2 63/4885NQO2 657/4885 |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2L2, NQO1 | RELA 6/4885NFE2L2 2/4885NQO2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.